Toxicities associated with immune checkpoint inhibitors - UpToDate
uptodate.com · 373 words · saved by 1 readers
{{configCtrl2.metaDescription()}}
Overview of toxicities associated with immune checkpoint inhibitors INTRODUCTION Immune checkpoint inhibitors (ICIs), also known as checkpoint inhibitor immunotherapy, are immunomodulatory antibodies that are used to enhance the immune system. These agents have substantially improved the prognosis for patients with many advanced malignancies. The primary targets for checkpoint inhibition include (table 1): ●Programmed cell death receptor 1 and programmed cell death ligand 1 – Multiple antibodies against programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1)…
related reading
- Immunotherapy for Cancer - NCIcancer.gov
- UpToDateuptodate.com
- Immunotherapy in pediatric malignancies: current status and future perspectives - PMCncbi.nlm.nih.gov
- Hepatic, pancreatic, and rare gastrointestinal complications of immune checkpoint inhibitor therapyuptodate.com
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanomanature.com
- UGCG and the glycosphingolipid rheostat: a metabolic checkpoint governing immune activation and tumor immune evasion | Signal Transduction and Targeted Therapynature.com
- Medicine's Endgamenotboring.co
- Cancer Study Links COVID Shots to Longer Survivalmedpagetoday.com
- The novel mechanism of lenalidomide activity - PMCncbi.nlm.nih.gov
- The blood cancer that became solvableworksinprogress.news
- Immune Regulation | People | Osaka University Immunology Frontier Research Centerifrec.osaka-u.ac.jp
- Classic Hodgkin lymphomapathologyoutlines.com